Haleon plc has commenced a share buyback programme with an aggregate consideration of up to £500 million. The company will purchase ordinary shares on the London Stock Exchange, CBOE Europe Limited, or Aquis through an agreement with Citigroup Global Markets Limited. Purchases must conclude by February 19, 2027. Approximately 80% of acquired shares will be cancelled, while the remainder will be held as treasury shares to satisfy obligations under employee share plans in 2027 and 2028. Haleon plc is a consumer health company focused on everyday health through brands such as Advil, Centrum, Panadol, and Sensodyne.
